Cortalix BV

Cortalix BV is focused on advancing biotechnology by developing novel synthetic single domain antibodies (sdAbs) for applications in diagnostics and therapeutics, especially in oncology and fibrotic diseases. Cortalix BV specializes in biotechnological innovations, specifically synthetic single domain antibodies. The company is based in Groningen, Netherlands and has engaged in 1 deal as of March 10, 2025. Cortalix raised EUR 1 million in a funding round led by Future Tech Ventures and Rabobank.

The company was founded by individuals with a background in biotechnology, though specific names are not available. Cortalix specializes in the development of innovative biotechnological solutions, primarily focusing on synthetic single domain antibodies (sdAbs), also known as nanobodies. The company’s core offerings include ImmunoPET imaging diagnostics, targeted radiotherapeutics, CAR-T immunotherapeutics, and bioanalytical tools, all designed to address various medical needs in the fields of oncology and fibrotic diseases. These products utilize a proprietary discovery platform that leverages synthetic sdAb libraries to create targeted therapies against fibrogenesis-related membrane receptors and proteins.

Cortalix collaborates with pharmaceutical companies, biotech firms, and academic institutions to deliver these specialized solutions, ensuring effective applications in molecular imaging and targeted therapies. The main geographical markets for these products extend beyond the Netherlands, reaching various regions in Europe, North America, and potentially other global markets where advanced cancer therapies are in demand. Cortalix generates revenue through a multifaceted business model that includes licensing agreements for internal programs, collaborations under partner programs, and fee-for-service projects. The company engages in transactions primarily through B2B partnerships, working directly with biotechnology and pharmaceutical companies, as well as contract research organizations (CROs).

Cortalix offers its services on a fee-for-service basis, which includes stand-alone sdAb selection and development projects tailored to meet specific client needs. These services typically involve detailed project scopes outlining the development of custom sdAbs for applications such as molecular imaging and therapeutic interventions. With a focus on high-value partnerships, Cortalix's revenue structure is designed to foster long-term collaborations that are beneficial to both the company and its clients. In March 2025, Cortalix BV raised EUR 1 million in venture funding from investors including Future Tech Ventures and Rabobank to accelerate the development and commercialization of its single-domain antibody technology.

The company plans to expand its product offerings by launching new immunotherapeutics and diagnostics, targeting release dates in the coming years. Additionally, Cortalix aims to penetrate new markets in Europe and North America, focusing on regions with a high demand for advanced cancer therapies by the end of 2025.